Johnson & Johnson (NYSE:JNJ) Stock Holdings Lessened by Summit Financial Strategies Inc.

Summit Financial Strategies Inc. lowered its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 7.7% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,462 shares of the company’s stock after selling 455 shares during the period. Summit Financial Strategies Inc.’s holdings in Johnson & Johnson were worth $968,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the stock. Riversedge Advisors LLC raised its stake in Johnson & Johnson by 8.6% during the 4th quarter. Riversedge Advisors LLC now owns 3,664 shares of the company’s stock valued at $627,000 after purchasing an additional 289 shares during the period. Insight Wealth Strategies LLC raised its stake in Johnson & Johnson by 22.0% during the 4th quarter. Insight Wealth Strategies LLC now owns 13,713 shares of the company’s stock valued at $2,346,000 after purchasing an additional 2,473 shares during the period. Northstar Group Inc. raised its stake in Johnson & Johnson by 2.3% during the 4th quarter. Northstar Group Inc. now owns 45,522 shares of the company’s stock valued at $7,788,000 after purchasing an additional 1,004 shares during the period. Ieq Capital LLC raised its stake in Johnson & Johnson by 3.6% during the 4th quarter. Ieq Capital LLC now owns 108,946 shares of the company’s stock valued at $18,637,000 after purchasing an additional 3,814 shares during the period. Finally, Raymond James Trust N.A. raised its stake in Johnson & Johnson by 1.3% during the 4th quarter. Raymond James Trust N.A. now owns 173,776 shares of the company’s stock valued at $29,728,000 after purchasing an additional 2,281 shares during the period. Institutional investors own 68.78% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on JNJ shares. UBS Group cut their target price on shares of Johnson & Johnson from $185.00 to $180.00 in a research note on Thursday, July 21st. Morgan Stanley upped their price target on shares of Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a research note on Friday, July 8th. The Goldman Sachs Group upped their price target on shares of Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 12th. Credit Suisse Group upped their price target on shares of Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 20th. Finally, Raymond James upped their price target on shares of Johnson & Johnson from $195.00 to $196.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 20th. Four equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $189.89.

Johnson & Johnson Stock Down 0.4 %

Shares of JNJ opened at $171.11 on Friday. The company has a 50-day simple moving average of $175.21 and a 200-day simple moving average of $174.55. The firm has a market capitalization of $449.88 billion, a P/E ratio of 24.91, a P/E/G ratio of 3.32 and a beta of 0.59. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.14 and a current ratio of 1.42. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.57 by $0.02. The business had revenue of $24.02 billion during the quarter, compared to analyst estimates of $23.85 billion. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.48 earnings per share. On average, equities research analysts expect that Johnson & Johnson will post 10.05 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be given a $1.13 dividend. This represents a $4.52 annualized dividend and a yield of 2.64%. The ex-dividend date is Monday, August 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is presently 65.79%.

Insider Buying and Selling

In related news, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the transaction, the executive vice president now owns 71,311 shares of the company’s stock, valued at $12,336,803. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the transaction, the executive vice president now owns 71,311 shares of the company’s stock, valued at $12,336,803. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Robert J. Decker sold 8,462 shares of the stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The disclosure for this sale can be found here. Company insiders own 0.35% of the company’s stock.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.